Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ARO-MMP7 Inhalation Solution
ARO-MMP7 · 1 trial · 1 indication
An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Arm | Type | Description |
|---|---|---|
| ARO-MMP7 | EXPERIMENTAL | single or multiple doses of ARO-MMP7 by inhalation of nebulized solution |
| Placebo | PLACEBO_COMPARATOR | single or multiple doses of placebo by inhalation of nebulized solution |
| Name | Type | Description |
|---|---|---|
| ARO-MMP7 Inhalation Solution | DRUG | ARO-MMP7 by inhalation of nebulized solution |
| Placebo | DRUG | Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution |
Inclusion Criteria (NHVs): * Normal pulmonary function tests at Screening * Normal electrocardiogram (ECG) at Screening * Non-smoking * Female participants cannot be pregnant or lactating * Male and female participants of childbearing potential must agree to use highly effective contraception and m...
Top 15 of 17 competitors
ARO-MMP7 is being developed for the treatment of idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. It is an investigational therapy and has not been approved for any indication. Clinical testing has so far involved both healthy participants and participants with idiopathic pulmonary fibrosis.
ARO-MMP7 is being developed by Arrowhead Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ARWR. The company is the sponsor of the clinical program evaluating the drug in idiopathic pulmonary fibrosis.
ARO-MMP7 is in Phase 1 clinical development. It is an investigational drug and is not FDA approved. One Phase 1 trial has been completed, and no active trials are currently listed for the program.
ARO-MMP7 has been studied in one Phase 1 trial, NCT05537025, titled Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis. The trial enrolled 105 participants, was randomized, double blind, and placebo controlled, and has completed. It ran in Denmark, Italy, New Zealand, South Korea, Spain, and the United Kingdom.
Yes. ARO-MMP7 Inhalation Solution is the alternative name for ARO-MMP7, referring to the inhaled formulation used in clinical testing. Both names describe the same investigational drug candidate being developed by Arrowhead Pharmaceuticals for idiopathic pulmonary fibrosis.